GB201311361D0 - Compounds and their therapeutic use - Google Patents

Compounds and their therapeutic use

Info

Publication number
GB201311361D0
GB201311361D0 GBGB1311361.8A GB201311361A GB201311361D0 GB 201311361 D0 GB201311361 D0 GB 201311361D0 GB 201311361 A GB201311361 A GB 201311361A GB 201311361 D0 GB201311361 D0 GB 201311361D0
Authority
GB
United Kingdom
Prior art keywords
compounds
therapeutic use
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1311361.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pimco 2664 Ltd
Original Assignee
Pimco 2664 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pimco 2664 Ltd filed Critical Pimco 2664 Ltd
Priority to GBGB1311361.8A priority Critical patent/GB201311361D0/en
Publication of GB201311361D0 publication Critical patent/GB201311361D0/en
Priority to SG11201510646SA priority patent/SG11201510646SA/en
Priority to NZ715192A priority patent/NZ715192A/en
Priority to EP14735642.2A priority patent/EP3013799B1/en
Priority to PL14735642T priority patent/PL3013799T3/pl
Priority to KR1020167002015A priority patent/KR102151299B1/ko
Priority to MX2015016914A priority patent/MX374328B/es
Priority to HK16105875.1A priority patent/HK1218115B/en
Priority to PCT/GB2014/051921 priority patent/WO2014207445A1/en
Priority to SI201430364T priority patent/SI3013799T1/sl
Priority to SM20170503T priority patent/SMT201700503T1/it
Priority to HUE14735642A priority patent/HUE034983T2/en
Priority to HRP20171611TT priority patent/HRP20171611T1/hr
Priority to MEP-2017-208A priority patent/ME02834B/me
Priority to PT147356422T priority patent/PT3013799T/pt
Priority to US14/899,422 priority patent/US9624167B2/en
Priority to JP2016522860A priority patent/JP6360555B2/ja
Priority to BR112015031527-5A priority patent/BR112015031527B1/pt
Priority to CN201480047140.2A priority patent/CN105492426B/zh
Priority to ES14735642.2T priority patent/ES2641758T3/es
Priority to AU2014300745A priority patent/AU2014300745B2/en
Priority to DK14735642.2T priority patent/DK3013799T3/en
Priority to RS20170876A priority patent/RS56256B1/sr
Priority to LTEP14735642.2T priority patent/LT3013799T/lt
Priority to CA2915075A priority patent/CA2915075C/en
Priority to EA201592308A priority patent/EA028077B1/ru
Priority to IL243103A priority patent/IL243103B/en
Priority to ZA2016/00202A priority patent/ZA201600202B/en
Priority to US15/484,256 priority patent/US9796670B2/en
Priority to CY20171101060T priority patent/CY1119438T1/el
Priority to US15/786,021 priority patent/US10029979B2/en
Priority to US16/037,048 priority patent/US10233147B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1311361.8A 2013-06-26 2013-06-26 Compounds and their therapeutic use Ceased GB201311361D0 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
GBGB1311361.8A GB201311361D0 (en) 2013-06-26 2013-06-26 Compounds and their therapeutic use
EA201592308A EA028077B1 (ru) 2013-06-26 2014-06-24 N-(4-гидрокси-4-метилциклогексил)-4-фенилбензолсульфонамиды и n-(4-гидрокси-4-метилциклогексил)-4-(2-пиридил)бензолсульфонамиды и их терапевтическое применение
PT147356422T PT3013799T (pt) 2013-06-26 2014-06-24 N-(4-hidroxi-4-metil-ciclohexil)-4-fenil-benzenossulfonamidas e n-(4-hidroxi-4-metil-ciclohexil)-4-(2-piridil)benzenossulfonamidas e a sua utilização terapêutica
US14/899,422 US9624167B2 (en) 2013-06-26 2014-06-24 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
EP14735642.2A EP3013799B1 (en) 2013-06-26 2014-06-24 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
PL14735642T PL3013799T3 (pl) 2013-06-26 2014-06-24 N-(4-hydroksy-4-metylocykloheksylo)-4-fenylobenzenosulfonamidy i N-(4-hydroksy-4- metylocykloheksylo)-4-(2-pirydylo)benzenosulfonamidy i ich zastosowanie terapeutyczne
KR1020167002015A KR102151299B1 (ko) 2013-06-26 2014-06-24 N-(4-하이드록시-4-메틸-사이클로헥실)-4-페닐-벤젠설폰아미드 및 n-(4-하이드록시-4-메틸-사이클로헥실)-4-(2-피리딜)벤젠설폰아미드 및 이들의 치료 용도
MX2015016914A MX374328B (es) 2013-06-26 2014-06-24 N-(4-hidroxi-4-metil-ciclohexil)-4-fenil-bencensulfonamidas y n-(4-hidroxi-4-metil-ciclohexil)-4-(2-piridil)bencensulfonamidas y su uso terapéutico.
HK16105875.1A HK1218115B (en) 2013-06-26 2014-06-24 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
PCT/GB2014/051921 WO2014207445A1 (en) 2013-06-26 2014-06-24 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
BR112015031527-5A BR112015031527B1 (pt) 2013-06-26 2014-06-24 N-(4-hidróxi-4-metil-ciclo-hexil)-4-fenil- benzenossulfonamidas e n-(4- hidróxi-4-metil-ciclo-hexil)-4-(2-piridil) benze-nossulfonamidas, seus usos, composição farmacêutica e seu método de preparação
SM20170503T SMT201700503T1 (it) 2013-06-26 2014-06-24 N-(4-idrossi-4-metil-cicloesil)-4-fenil-benzensolfonammidi e n-(4-idrossi-4-metil-cicloesil)-4- (2-piridil)benzensolfonammidi e loro uso terapeutico
HUE14735642A HUE034983T2 (en) 2013-06-26 2014-06-24 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
HRP20171611TT HRP20171611T1 (hr) 2013-06-26 2014-06-24 N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidi i n-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidi i njihova terapeutska primjena
MEP-2017-208A ME02834B (me) 2013-06-26 2014-06-24 N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamid i n-(4-hidroksi-4-metilcikloheksil)- 4-(2-piridil)benzensulfonamid i nihova terapijska upotreba
SG11201510646SA SG11201510646SA (en) 2013-06-26 2014-06-24 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
JP2016522860A JP6360555B2 (ja) 2013-06-26 2014-06-24 Ｎ−（４−ヒドロキシ−４−メチル−シクロヘキシル）−４−フェニル−ベンゼンスルホンアミド及びｎ−（４−ヒドロキシ−４−メチル−シクロヘキシル）−４−（２−ピリジル）ベンゼンスルホンアミド、並びにそれらの治療的使用
CN201480047140.2A CN105492426B (zh) 2013-06-26 2014-06-24 N‑(4‑羟基‑4‑甲基‑环己基)‑4‑苯基‑苯磺酰胺和n‑(4‑羟基‑4‑甲基‑环己基)‑4‑(2‑吡啶基)苯磺酰胺和其治疗性用途
SI201430364T SI3013799T1 (sl) 2013-06-26 2014-06-24 N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidi in N-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)benzensulfonamidi in njihova terapevtska uporaba
NZ715192A NZ715192A (en) 2013-06-26 2014-06-24 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
ES14735642.2T ES2641758T3 (es) 2013-06-26 2014-06-24 N-(4-hidroxi-4-metil-ciclohexil)-4-fenil-bencenosulfonamidas y N-(4-hidroxi-4-metil-ciclohexil)-4-(2-piridil)bencenosulfonamidas y su uso terapéutico
AU2014300745A AU2014300745B2 (en) 2013-06-26 2014-06-24 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
DK14735642.2T DK3013799T3 (en) 2013-06-26 2014-06-24 N- (4-HYDROXY-4-METHYL-CYCLOHEXYL) -4-PHENYL-BENZENESULPHONAMIDES AND N- (4-HYDROXY-4-METHYL-CYCLOHEXYL) -4- (2-PYRIDYL) -BENZENESULPHONAMIDES AND THEIR THERAPEES
RS20170876A RS56256B1 (sr) 2013-06-26 2014-06-24 N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamid i n-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)benzensulfonamid i njihova terapijska upotreba
LTEP14735642.2T LT3013799T (lt) 2013-06-26 2014-06-24 N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidai ir n-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)benzensulfonamidai bei jų terapinis panaudojimas
CA2915075A CA2915075C (en) 2013-06-26 2014-06-24 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
IL243103A IL243103B (en) 2013-06-26 2015-12-14 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their medical use
ZA2016/00202A ZA201600202B (en) 2013-06-26 2016-01-11 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
US15/484,256 US9796670B2 (en) 2013-06-26 2017-04-11 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
CY20171101060T CY1119438T1 (el) 2013-06-26 2017-10-11 Ν-(4-υδροξυ-4-μεθυλ-κυκλοεξυλ)-4-φαινυλ-βενζολοσουλφοναμιδια και ν-(4-υδροξυ-4-μεθυλ-κυκλοεξυλ)-4-(2-πυριδυλ)βενζολοσουλφοναμιδια και η θεραπευτικη τους χρηση
US15/786,021 US10029979B2 (en) 2013-06-26 2017-10-17 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
US16/037,048 US10233147B2 (en) 2013-06-26 2018-07-17 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1311361.8A GB201311361D0 (en) 2013-06-26 2013-06-26 Compounds and their therapeutic use

Publications (1)

Publication Number Publication Date
GB201311361D0 true GB201311361D0 (en) 2013-08-14

Family

ID=48998987

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1311361.8A Ceased GB201311361D0 (en) 2013-06-26 2013-06-26 Compounds and their therapeutic use

Country Status (28)

Country Link
US (4) US9624167B2 (https=)
EP (1) EP3013799B1 (https=)
JP (1) JP6360555B2 (https=)
KR (1) KR102151299B1 (https=)
CN (1) CN105492426B (https=)
AU (1) AU2014300745B2 (https=)
BR (1) BR112015031527B1 (https=)
CA (1) CA2915075C (https=)
CY (1) CY1119438T1 (https=)
DK (1) DK3013799T3 (https=)
EA (1) EA028077B1 (https=)
ES (1) ES2641758T3 (https=)
GB (1) GB201311361D0 (https=)
HR (1) HRP20171611T1 (https=)
HU (1) HUE034983T2 (https=)
IL (1) IL243103B (https=)
LT (1) LT3013799T (https=)
ME (1) ME02834B (https=)
MX (1) MX374328B (https=)
NZ (1) NZ715192A (https=)
PL (1) PL3013799T3 (https=)
PT (1) PT3013799T (https=)
RS (1) RS56256B1 (https=)
SG (1) SG11201510646SA (https=)
SI (1) SI3013799T1 (https=)
SM (1) SMT201700503T1 (https=)
WO (1) WO2014207445A1 (https=)
ZA (1) ZA201600202B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
SI3262028T1 (sl) * 2014-12-17 2022-02-28 Pimco 2664 Limited N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidne in N-(-4hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidne spojine in njihova terapevtska uporaba
GB201813312D0 (en) 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
GB201905520D0 (en) * 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
EP4431090A1 (en) 2023-03-15 2024-09-18 Istesso 1 Limited Solfonamides acting as mitochondrial complex i modulator compounds
GB202308547D0 (en) 2023-06-08 2023-07-26 Istesso 2 Ltd Tnf inhibitor combination therapies
GB202309515D0 (en) 2023-06-23 2023-08-09 Istesso 2 Ltd JAK inhibitor and IL-6 inhibitor combination therapies
GB202315822D0 (en) 2023-10-16 2023-11-29 Istesso 3 Ltd Anti-fibrotic combination therapeutics
GB202317050D0 (en) 2023-11-07 2023-12-20 Istesso 2 Ltd Disease modifying anti-rheumatic drug combination therapies
EP4647071A1 (en) 2024-05-10 2025-11-12 Istesso Therapeutics Limited Mitochondrial complex i modulator for use in the treatment of arthritis
GB202411554D0 (en) 2024-08-06 2024-09-18 Istesso 2 Ltd NF-kB inhibitor combination therapies

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB597810A (en) 1943-04-12 1948-02-04 Gen Printing Ink Corp Improvements in or relating to derivatives of diphenyl
DE1046220B (de) 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
US4119784A (en) 1977-07-01 1978-10-10 American Cyanamid Company Anionic substituted sulfonamido biphenyls
DE3000519A1 (de) 1979-02-01 1980-08-14 Byk Gulden Lomberg Chem Fab Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel
DE3535167A1 (de) 1985-10-02 1987-04-09 Boehringer Mannheim Gmbh Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
SK56798A3 (en) 1995-10-30 1998-12-02 Smithkline Beecham Corp Protease inhibitors, pharmaceutical composition containing them and their use
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
JP2001527513A (ja) 1996-03-15 2001-12-25 デュポン ファーマシューティカルズ カンパニー スピロ環インテグリン阻害剤
EP0939629A4 (en) 1996-07-22 2002-07-17 Monsanto Co THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS
AU731737B2 (en) 1996-10-16 2001-04-05 Wyeth Holdings Corporation The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
WO1998023608A1 (en) 1996-11-27 1998-06-04 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
WO1998043962A1 (en) 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
CA2289602A1 (en) 1997-05-08 1998-11-12 William Edward Bondinell Protease inhibitors
DE59802394D1 (de) 1997-05-09 2002-01-24 Hoechst Ag Substituierte Diaminocarbonsäuren
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
IL137423A0 (en) 1998-01-23 2001-07-24 Aventis Pharma Gmbh Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
RU2208609C2 (ru) 1998-02-04 2003-07-20 Новартис Аг Сульфониламинопроизводные, которые ингибируют разлагающие матрикс металлопротеиназы
JPH11246527A (ja) 1998-03-02 1999-09-14 Shionogi & Co Ltd Ｍｍｐ−８阻害剤
DE19815547C1 (de) 1998-04-07 1999-12-02 Joachim Schmidt Haftmittel für Zahnprothesen
EP0960882A1 (en) 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
RU2002128015A (ru) 2000-03-21 2004-02-27 Дзе Проктер Энд Гэмбл Компани (US) Содержащие карбоциклическую боковую цепь n-замещенные ингибиторы металлопротеаз
US6723733B2 (en) 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
WO2002060867A2 (en) 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
JPWO2002074298A1 (ja) 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
JP2004535390A (ja) 2001-05-07 2004-11-25 スミスクライン・ビーチャム・コーポレイション スルホンアミド
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
GB0126157D0 (en) 2001-10-31 2002-01-02 Univ Aberdeen Therapeutic compounds
TW200305396A (en) 2002-03-27 2003-11-01 Shionogi & Co Cartilage extracellular matrix degradation
WO2004022561A1 (en) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
DE10251170A1 (de) 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
ATE380025T1 (de) 2003-05-07 2007-12-15 Univ Aberdeen Ketone und reduzierte ketone als therapeutische mittel zur behandlung von knochenerkrankungen
WO2004106290A1 (ja) 2003-05-14 2004-12-09 Kissei Pharmaceutical Co., Ltd. アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途
AR046330A1 (es) 2003-09-09 2005-12-07 Japan Tobacco Inc Inhibidor de dipeptidilpeptidasa iv
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
AP2006003633A0 (en) 2003-12-19 2006-06-30 Pfizer Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-BETA-hydroxysteroid dehydrogenase type 1 (11-BETA-HSD-1) for the treatment of diabetes and obesity
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
GB0405193D0 (en) 2004-03-08 2004-04-21 Medical Res Council Compounds
US20080255240A1 (en) 2004-05-05 2008-10-16 Novo Nordisk A/S Sulfonamide Derivatives
GB0412553D0 (en) 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
US7470722B2 (en) 2004-06-10 2008-12-30 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
EP1807391A4 (en) 2004-10-29 2010-01-06 Astrazeneca Ab NOVEL SULFONAMIDE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
AU2006257646A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-YL)-sulfonamide derivatives
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
TW200720261A (en) 2005-08-31 2007-06-01 Sankyo Co Phenylene derivatives
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
DK1984344T3 (da) 2005-12-29 2013-01-14 Lexicon Pharmaceuticals Inc Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf
US7560597B2 (en) 2007-03-08 2009-07-14 The University Court Of The University Of Aberdeen 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
WO2010025235A1 (en) 2008-08-29 2010-03-04 Regents Of The University Of Michigan Selective ligands for the dopamine 3 (d3) receptor and methods of using the same
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0817207D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
SI3262028T1 (sl) 2014-12-17 2022-02-28 Pimco 2664 Limited N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidne in N-(-4hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidne spojine in njihova terapevtska uporaba

Also Published As

Publication number Publication date
HK1218115A1 (en) 2017-02-03
ES2641758T3 (es) 2017-11-13
SI3013799T1 (sl) 2017-10-30
HRP20171611T1 (hr) 2017-12-15
NZ715192A (en) 2020-08-28
AU2014300745B2 (en) 2018-10-04
JP2016529218A (ja) 2016-09-23
US20170217881A1 (en) 2017-08-03
MX374328B (es) 2025-03-06
US9796670B2 (en) 2017-10-24
KR20160024392A (ko) 2016-03-04
SG11201510646SA (en) 2016-01-28
BR112015031527B1 (pt) 2023-04-11
CN105492426A (zh) 2016-04-13
KR102151299B1 (ko) 2020-09-02
CA2915075A1 (en) 2014-12-31
MX2015016914A (es) 2016-06-15
US20160145206A1 (en) 2016-05-26
JP6360555B2 (ja) 2018-07-18
US9624167B2 (en) 2017-04-18
IL243103B (en) 2019-09-26
SMT201700503T1 (it) 2017-11-15
CA2915075C (en) 2021-02-16
WO2014207445A1 (en) 2014-12-31
CN105492426B (zh) 2018-01-12
EA028077B1 (ru) 2017-10-31
LT3013799T (lt) 2017-09-25
ME02834B (me) 2018-01-20
ZA201600202B (en) 2017-04-26
PL3013799T3 (pl) 2018-01-31
US10233147B2 (en) 2019-03-19
RS56256B1 (sr) 2017-11-30
CY1119438T1 (el) 2018-03-07
AU2014300745A1 (en) 2016-02-11
US20180319742A1 (en) 2018-11-08
BR112015031527A2 (pt) 2017-07-25
US20180037544A1 (en) 2018-02-08
EP3013799A1 (en) 2016-05-04
PT3013799T (pt) 2017-10-03
EP3013799B1 (en) 2017-07-26
IL243103A0 (en) 2016-02-01
HUE034983T2 (en) 2018-05-02
EA201592308A1 (ru) 2016-07-29
DK3013799T3 (en) 2017-09-18
US10029979B2 (en) 2018-07-24

Similar Documents

Publication Publication Date Title
GB201320729D0 (en) Therapeutic compounds and their use
ZA201506487B (en) Therapeutic compounds and compositions
GB201321743D0 (en) Therapeutic agents
GB201321746D0 (en) Therapeutic agents
GB201321738D0 (en) Therapeutic Agents
GB201321736D0 (en) Therapeutic agents
GB201321729D0 (en) Therapeutic agents
GB201321733D0 (en) Therapeutic agents
GB201321728D0 (en) Therapeutic agents
GB201321739D0 (en) Therapeutic agents
GB201321730D0 (en) Therapeutic agents
GB201321741D0 (en) Therapeutic agents
GB201321740D0 (en) Therapeutic agents
GB201321732D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
GB201321744D0 (en) Therapeutic agents
GB201321737D0 (en) Therapeutic Agents
GB201311361D0 (en) Compounds and their therapeutic use
GB201321748D0 (en) Therapeutic agents
GB201321742D0 (en) Therapeutic agents
GB201321735D0 (en) Therapeutic Agents
GB201321745D0 (en) Therapeutic agents
GB201308440D0 (en) Therapeutic
GB201321731D0 (en) Therapeutic agents
ZA201607581B (en) Dosage forms and therapeutic uses l-4lchlorokynurenine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
AT Applications terminated before publication under section 16(1)